Targeting the LRP5 Pathway Improves Bone Properties in a Mouse Model of Osteogenesis Imperfecta |
| |
| Authors: | Christina M Jacobsen Lauren A Barber Ugur M Ayturk Heather J Roberts Lauren E Deal Marissa A Schwartz MaryAnn Weis David Eyre David Zurakowski Alexander G Robling Matthew L Warman |
| |
| Affiliation: | 1. Orthopaedic Research Laboratories, Department of Orthopaedic Surgery, Boston Children's Hospital, Boston, MA, USA;2. Division of Endocrinology, Boston Children's Hospital, Boston, MA, USA;3. Division of Genetics, Boston Children's Hospital, Boston, MA, USA;4. Department of Pediatrics, Harvard Medical School, Boston, MA, USA;5. Department of Genetics, Harvard Medical School, Boston, MA, USA;6. Department of Anatomy and Cell Biology, Indiana University, Indianapolis, IN, USA;7. Department of Orthopedics and Sports Medicine, University of Washington, Seattle, WA, USA;8. Department of Anesthesia, Children's Hospital Boston, Boston, MA, USA;9. Howard Hughes Medical Institute, Boston, MA, USA |
| |
| Abstract: | The cell surface receptor low‐density lipoprotein receptor‐related protein 5 (LRP5) is a key regulator of bone mass and bone strength. Heterozygous missense mutations in LRP5 cause autosomal dominant high bone mass (HBM) in humans by reducing binding to LRP5 by endogenous inhibitors, such as sclerostin (SOST). Mice heterozygous for a knockin allele (Lrp5p.A214V) that is orthologous to a human HBM‐causing mutation have increased bone mass and strength. Osteogenesis imperfecta (OI) is a skeletal fragility disorder predominantly caused by mutations that affect type I collagen. We tested whether the LRP5 pathway can be used to improve bone properties in animal models of OI. First, we mated Lrp5+/p.A214V mice to Col1a2+/p.G610C mice, which model human type IV OI. We found that Col1a2+/p.G610C;Lrp5+/p.A214V offspring had significantly increased bone mass and strength compared to Col1a2+/p.G610C;Lrp5+/+ littermates. The improved bone properties were not a result of altered mRNA expression of type I collagen or its chaperones, nor were they due to changes in mutant type I collagen secretion. Second, we treated Col1a2+/p.G610C mice with a monoclonal antibody that inhibits sclerostin activity (Scl‐Ab). We found that antibody‐treated mice had significantly increased bone mass and strength compared to vehicle‐treated littermates. These findings indicate increasing bone formation, even without altering bone collagen composition, may benefit patients with OI. © 2014 American Society for Bone and Mineral Research. |
| |
| Keywords: | OSTEOGENESIS IMPERFECTA DISEASES AND DISORDERS OF BONE WNT/BETA‐CATENIN/LRPS CELL/TISSUE SIGNALING PARACRINE PATHWAYS ANABOLICS GENETIC ANIMAL MODELS |
|
|
